Lantz Financial LLC Lowers Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Lantz Financial LLC cut its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,233 shares of the biopharmaceutical company's stock after selling 3,367 shares during the period. Lantz Financial LLC's holdings in Gilead Sciences were worth $2,491,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. HHM Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $28,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $31,000. Stephens Consulting LLC lifted its holdings in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new stake in Gilead Sciences during the 4th quarter valued at about $33,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

NASDAQ:GILD traded down $1.17 during trading hours on Monday, hitting $108.91. 9,986,911 shares of the stock were exchanged, compared to its average volume of 7,723,769. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm's fifty day moving average price is $105.49 and its 200 day moving average price is $100.90. The company has a market cap of $135.48 billion, a P/E ratio of 294.35, a P/E/G ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 52-week low of $62.69 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business's revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.32) earnings per share. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.90%. Gilead Sciences's payout ratio is 66.53%.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now directly owns 121,152 shares in the company, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,929 shares of company stock worth $5,644,780 over the last ninety days. Corporate insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. BMO Capital Markets raised their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Royal Bank of Canada raised their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.